phone+44 203 371 1100

Gilead Sciences, Inc.

Credit Sector:- Health Care

Country:- United States

Bond Document:- https://www.bondpdf.com

In order to view the complete data, please login here

List of Corporate Actions

Announcement Date CA Type CA Impact CA Event ISIN
02-Mar-2020 Propose Acquisition Target Name Forty Seven, Inc. US00214WAE12
Gilead Sciences, Inc. today announced that it intends to acquire shares in Forty Seven, Inc.
08-May-2020 Propose Asset Acquisition - - US00214WAE12
Gilead Sciences, Inc. today announced that it intends to acquire developments Lefitolimod and Enandim from Mologen AG.
23-Jun-2020 Offer Purchase Stock Target Name Pionyr Immunotherapeutics, Inc. US00214WAE12
Gilead Sciences, Inc. today announces that it has entered into an definitive agreement to acquire 49.9 percent equity interest in Pionyr Immunotherapeutics, Inc.
21-Jul-2020 Offer Purchase Stock Target Name Tizona Therapeutics, Inc. US00214WAE12
Gilead Sciences, Inc. announced today that it intends to acquire 49.9 percent equity interest in Tizona Therapeutics, Inc.
24-Sep-2020 New Bond - - US375558BY84
Gilead Sciences, Inc. has issued USD 1MMM, 1.650% fixed rate bond due 01-Oct-2030.

View more details

FactEntry

All of the financial data available on this page is sourced from FactEntry.